A Radiolabeled Oligonucleotide Ligation Assay Demonstrates the High Frequency of Nevirapine Resistance Mutations in HIV Type 1 Quasispecies of NVP-Treated and Untreated Mother–Infant Pairs from Uganda
| Autor: | Christopher C. Whalen, Francis Bajunirwe, Peter Mugyenyi, Aslam Syed, Erika Fraundorf, Fred Kyeyune, Eric J. Arts, Korey Demers, Ryan M. Troyer, Matthew S. Lalonde |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Nevirapine
Anti-HIV Agents Immunology Population Mutation Missense Mothers HIV Infections Drug resistance Viral quasispecies medicine.disease_cause Polymerase Chain Reaction Virus immune system diseases Virology Drug Resistance Viral medicine Cluster Analysis Humans Uganda education Phylogeny Recombination Genetic education.field_of_study Mutation biology Infant Newborn Infant virus diseases Sequence Analysis DNA biochemical phenomena metabolism and nutrition biology.organism_classification HIV Reverse Transcriptase Reverse transcriptase Infectious Diseases Amino Acid Substitution Genetic Techniques DNA Viral Lentivirus HIV-1 Leukocytes Mononuclear Zidovudine medicine.drug |
| Zdroj: | AIDS Research and Human Retroviruses. 24:235-250 |
| ISSN: | 1931-8405 0889-2229 |
| Popis: | This study explores the levels of NVP and AZT resistance mutations in untreated, NVP- or AZT-treated mother-infant pairs in Uganda. PCR-amplified reverse transcriptase (RT) gene fragments derived from PBMC samples of 85 mothers (10 AZT treated, 35 NVP treated, and 40 untreated) and their 52 infected infants (5 AZT, 9 NVP, and 38 untreated) were classified as subtype A (59%), D (29%), C (3%), and recombinant forms (9%) by population sequencing. Only 16% of the NVP-treated infected mothers and infants harbored either the K103N or the Y181C at 6 weeks postdelivery. The majority of these samples (n = 107) were then analyzed using a radiolabeled oligonucleotide ligation assay (OLA) specific for K70R, K103N, and Y181C, using nonstandard bases to accommodate sequence heterogeneity. By OLA, 43% of the NVP-treated group had K103N and/or Y181C mutations in their HIV-1 population, using >0.6% cutoff based on a comparative clonal analysis of clinical isolates. Surprisingly, an equal fraction of the untreated and NVP-treated mother-infant group had the K103N mutation in their HIV-1 population in the range of 0.6-5%. These findings suggest a relatively high frequency of K103N mutation in the drug-naive, subtype A and D infected Ugandan population as compared to the very low frequency of the Y181C and K70R mutation ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|